ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO999

Impact of Sparsentan on Quality of Life (QoL) in Focal Segmental Glomerulosclerosis (FSGS) Patients in DUET: An Interim Analysis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Trachtman, Howard, NYU School of Medicine, New York, New York, United States
  • Hogan, Jonathan J., University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Ferguson, Beatrice, Retrophin, Inc., San Diego, California, United States
  • Komers, Radko, Retrophin, Inc., San Diego, California, United States

FSGS has been shown to impair patients’ (pts) QoL. DUET, a phase 2, randomized, active-control study, examined QoL in pts with FSGS.


In the 8-week randomized double-blind treatment period (DB), pts received sparsentan (SPAR) or irbesartan (IRB), after which all randomized pts who continued in an open-label extension received SPAR (SPAR:SPAR or IRB:SPAR, respectively). The SF-36 questionnaire was administered to adults at baseline (BL), Week 8, Week 48 and Week 144. Norm-based scoring was used for the physical (PCS) and mental (MCS) component scores (mean±SD).


Seventy-three patients were randomized to SPAR and 36 to IRB with a mean baseline UP/C of 3.61 and 3.12 g/g, respectively, and median eGFR of 73.4 and 65.1 mL/min/1.73 m2, respectively. There were no clinically meaningful differences between the SPAR and IRB groups in the cross-sectional PCS or MCS at BL and Week 8. The mean change from BL to Week 8 between the SPAR and IRB groups for PCS (p=0.5103) and MCS (p=0.8725) did not differ. Importantly, there were no meaningful changes over time during the open-label extension in PCS or MCS from BL to Week 48, or Week 144 both in SPAR:SPAR and IRB:SPAR (Table).


Using the SF-36, the physical and mental QoL component scores in DUET were similar in SPAR- and IRB-treated patients during the DB. QoL parameters remained stable over time (2 years) in participants electing to remain on long-term open-label treatment with SPAR regardless of original randomization to SPAR or IRB and were not adversely affected by dual blockade of the AT1 and ETA receptors.

Table. Cross-Sectional Mean±SD for PCS and MCS
Week 0
Week 8
Week 48
Week 144
Week 0
Week 8
Week 48
Week 144
PCS, mean±SD49±849±949±949±950±750±753±553±6
MCS, mean±SD50±1050±952±1052±950±1150±1052±650±7


  • Commercial Support